Strategic partnerships Almac Discovery emphasizes collaboration with industrial and academic partners to translate early stage oncology research to therapeutics, presenting a sales opportunity to position as a collaborative drug discovery partner for biotech and pharma companies seeking early-stage oncology programs.

Clinical development access Leverage access to Almac Group’s broader pharmaceutical development capabilities, as Almac Discovery can engage in clinical stage oncology discovery and development, offering a pathway for partners to move from discovery to early clinical development with a single ecosystem.

Lead program potential ALM201 is in clinical development, signaling near-term collaboration potential around a lead oncology program, with opportunity to engage in co-development, licensing discussions, or milestone-driven partnerships tied to clinical progress.

Capabilities and tech Almac Discovery’s capabilities in ubiquitin specific proteases and protein drug conjugates, plus access to cGMP flow hydrogenation and advanced analytics, provide a broad technical platform to pitch for specialized drug discovery needs and differentiated services.

ESG and ecosystem Recent collaborations and ESG-aligned initiatives (ESG Backer with Young Enterprise NI, partnerships with academic and industry networks) create a value proposition for partners prioritizing responsible innovation, workforce development, and regional life sciences ecosystems as part of a joint value story.